Oric Pharmaceuticals

ORIC

Market cap $1.05B

Overview Fund Activity

10.78 USD

-0.08

0.74%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

10.61

-0.17

1.58%

1 day

-0.74%

5 days

-0.92%

1 month

13.24%

3 months

11.48%

6 months

34.75%

Year to date

30.51%

1 year

18.98%

5 years

-50.71%

10 years

-58.17%

About: ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.

Employees: 128

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

10,102% more call options, than puts

Call options by funds: $10.5M | Put options by funds: $103K

140% more funds holding in top 10

Funds holding in top 10: 5 [Q1] → 12 (+7) [Q2]

114% more capital invested

Capital invested by funds: $442M [Q1] → $947M (+$505M) [Q2]

6% less first-time investments, than exits

New positions opened: 33 | Existing positions closed: 35

1.98% less ownership

Funds ownership: 111.52% [Q1] → 109.53% (-1.98%) [Q2]

2% less funds holding

Funds holding: 143 [Q1] → 140 (-3) [Q2]

16% less repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 51

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$15

39% upside

Avg. target

$17.4

61% upside

High target

$19

76% upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

Guggenheim Brad Canino	$18	Buy Assumed	4 Sep 2025
JP Morgan Anupam Rama	$17	Overweight Maintained	14 Aug 2025
HC Wainwright & Co. Robert Burns	$19	Buy Maintained	14 Aug 2025
Guggenheim Michael Schmidt	$18	Buy Reiterated	13 Aug 2025
Ladenburg Thalmann Kevin DeGeeter	$15	Buy Initiated	8 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about ORIC published over the past 30 days

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on September 2, 2025 (the “Grant Date”), ORIC granted a total of 292,500 non-qualified stock options and 79,000 restricted stock units to one new non-executive officer employee who began their employment with ORIC in August 2025.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC Pharmaceuticals, Inc. (ORIC) Pharmaceuticals, Inc. Presents At Citi's Biopharma Back To School Conference Transcript

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC ) Pharmaceuticals, Inc. Citi's Biopharma Back to School Conference September 3, 2025 4:00 PM EDT Company Participants Jacob Chacko - President, CEO & Director Dominic Piscitelli - Chief Financial Officer Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research Division Presentation Yigal Nochomovitz Director and SMid Cap Biotech Analyst Welcome back everyone. This is final session of the second day of the Biopharma Back to School Summit.

ORIC Pharmaceuticals, Inc. (ORIC) Pharmaceuticals, Inc. Presents At Citi's Biopharma Back To School Conference Transcript

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will be participating in the following investor conferences in September:

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Kevin Brodbeck, PhD, to the newly established role of Chief Technical Officer (CTO). Dr. Brodbeck brings more than 25 years of experience leading technical operations, quality assurance, chemistry, manufacturing and controls (CMC), and regulatory activities across a wide range of pharmaceutical products at all stages of development and commercialization. The creation of the CTO role and Dr. Brodbeck's appointment reflect the impending advancement of ORIC's clinical programs into late-stage development with the potential start of Phase 3 trials for ORIC-944 and enozertinib (ORIC-114) in 2026.

ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer

ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates

Reported potentially best-in-class clinical efficacy and safety data from ongoing Phase 1b trial of ORIC-944 in combination with AR inhibitors for the treatment of patients with mCRPC Strengthened cash position with $244 million gross proceeds from top-tier healthcare specialist investors across $125 million private placement financing and $119 million ATM issuances; Following recent financing activity, ORIC concludes anticipated ATM facility usage In anticipation of potential initiation of registrational trials in 2026 for ORIC-944 and ORIC-114 (enozertinib), the company has revised its operating plan to substantially reduce investment in discovery research Under the revised operating plan and with the additional financing, cash and investments expected to provide runway into 2H 2028 (previously 2H 2027) and beyond anticipated primary endpoint readouts from first Phase 3 trials for ORIC-944 and ORIC-114 (enozertinib) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 12, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter ended June 30, 2025.

ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on August 1, 2025 (the “Grant Date”), ORIC granted a total of 35,000 non-qualified stock options and 5,800 restricted stock units to two new non-executive employees who began their employment with ORIC in July 2025.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

Oric Pharmaceuticals, Inc. (ORIC) Now Trades Above Golden Cross: Time to Buy?

From a technical perspective, Oric Pharmaceuticals, Inc. (ORIC) is looking like an interesting pick, as it just reached a key level of support. ORIC's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.

Oric Pharmaceuticals, Inc. (ORIC) Now Trades Above Golden Cross: Time to Buy?

Zacks Investment Research

Oric Pharmaceuticals, Inc. (ORIC) is a Great Momentum Stock: Should You Buy?

Does Oric Pharmaceuticals, Inc. (ORIC) have what it takes to be a top stock pick for momentum investors? Let's find out.

Oric Pharmaceuticals, Inc. (ORIC) is a Great Momentum Stock: Should You Buy?

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on July 1, 2025 (the “Grant Date”), ORIC granted a total of 9,000 non-qualified stock options and 1,600 restricted stock units to one new non-executive employee who began their employment with ORIC in June 2025.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

All You Need to Know About Oric Pharmaceuticals (ORIC) Rating Upgrade to Buy

Oric Pharmaceuticals (ORIC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Oric Pharmaceuticals (ORIC) Rating Upgrade to Buy

See News Rankings

Charts implemented using Lightweight Charts™